Berckmans, Y.; Hoffert, Y.; Vankerckhoven, A.; Dreesen, E.; Coosemans, A.
Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates. Pharmaceutics 2023, 15, 1792.
https://doi.org/10.3390/pharmaceutics15071792
AMA Style
Berckmans Y, Hoffert Y, Vankerckhoven A, Dreesen E, Coosemans A.
Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates. Pharmaceutics. 2023; 15(7):1792.
https://doi.org/10.3390/pharmaceutics15071792
Chicago/Turabian Style
Berckmans, Yani, Yannick Hoffert, Ann Vankerckhoven, Erwin Dreesen, and An Coosemans.
2023. "Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates" Pharmaceutics 15, no. 7: 1792.
https://doi.org/10.3390/pharmaceutics15071792
APA Style
Berckmans, Y., Hoffert, Y., Vankerckhoven, A., Dreesen, E., & Coosemans, A.
(2023). Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates. Pharmaceutics, 15(7), 1792.
https://doi.org/10.3390/pharmaceutics15071792